Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases

• Published in: British journal of pharmacology Vol. 175; no. 8; pp. 1230 - 1240
• Main Authors: Zhang, Song‐Yang, Xu, Ming‐Jiang, Wang, Xian
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.04.2018; John Wiley and Sons Inc
• Subjects: Adrenomedullin; Amylin; Animals; Calcitonin gene-related peptide; Cardiovascular diseases; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - metabolism; Cardiovascular system; Humans; Metabolic Diseases - drug therapy; Metabolic Diseases - metabolism; Peptide Hormones - pharmacology; Peptide Hormones - therapeutic use; Receptors, Peptide - metabolism; Review; Themed Section: Review
• ISSN: 0007-1188; 1476-5381; 1476-5381
• DOI: 10.1111/bph.13814

Adrenomedullin (ADM) 2/intermedin (IMD) is a short peptide that belongs to the CGRP superfamily. Although it shares receptors with CGRP, ADM and amylin, ADM2 has significant and unique functions in the cardiovascular system. In the past decade, the cardiovascular effect of ADM2 has been carefully analysed. In this review, progress in understanding the effects of ADM2 on the cardiovascular system and its protective role in cardiometabolic diseases are summarized. Linked Articles This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc